Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  recombinant interferon alfa-2b
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 27 for your search:
Start Over
Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181203, DARENCA STUDY 2, NCT01339962
Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 to 90
Sponsor: Other
Protocol IDs: R-2012-785-094, NCT02199327
PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: 9267-01, 2001-034, NCT00221702
GEM05 for Patients With Multiple Myeloma Under 65 Years
Phase: Phase III
Type: Treatment
Status: Completed
Age: 65 and under
Sponsor: Other
Protocol IDs: 2005-001110-41, NCT00461747
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Phase: Phase III
Type: Treatment
Status: Closed
Age: Not specified
Sponsor: NCI
Protocol IDs: NCI-2009-00778, CDR0000579151, SWOG-S0518, S0518, U10CA032102, NCT00569127
SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 00041, U01CA062505, P30CA033572, CHNMC-PHII-23, NCI-T99-0085, CDR0000068262, T99-0085, NCT00006384
Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181065, NCT00267748
Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 05-125, NCT00610857
Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: TORAVA, ET2007-035, NCT00619268
Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: LUD2007-001, UPCI07-023, UCH15689B, NCT00679289
Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNa-2b in Metastatic Renal Cell Carcinoma (RCC) Patients
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: D0708, R01CA095648, NCT00913913
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: not specified
Sponsor: Other
Protocol IDs: CASE2609, NCI-2010-00640, NCT01100528
Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CASE8805, NCI-2010-01390, NCT01158534
Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: DARENCA-1, NCT01274273
Advanced Cervical Cancer Trial in India
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: Not specified
Sponsor: Other
Protocol IDs: 464.05, NCT01276730
5-FU Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-09, NCT01658813
Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01347, NCI-5633, OSU-2005H0005, CDR0000439532, OSU 0312, 5633, P30CA016058, U01CA076576, 0312, NCT00217373
Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00152, YALE HIC#27409, NCI-7317, CDR0000441640, 7317, NCT00217542
Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000511743, UCSD-060199, PHARMION-UCSD-060199, NCT00398450
Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-0354, NCT00629200
Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2009-0124, NCT00970996
Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CASE-CCF-7509, P30CA043703, CASE-CCF-1062, IRB 7059, NCT00311558
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CASE3Y06, P30CA043703, NCT00498979
Start Over